- Home
- EHAB vs TERN Comparison
EHAB vs TERN Comparison
Compare EHAB & TERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EHAB
- TERN
- Stock Information
- Founded
- EHAB 2014
- TERN 2017
- Country
- EHAB United States
- TERN United States
- Employees
- EHAB N/A
- TERN N/A
- Industry
- EHAB Hospital/Nursing Management
- TERN Biotechnology: Pharmaceutical Preparations
- Sector
- EHAB Health Care
- TERN Health Care
- Exchange
- EHAB Nasdaq
- TERN Nasdaq
- Market Cap
- EHAB 401.6M
- TERN 298.1M
- IPO Year
- EHAB N/A
- TERN 2021
- Fundamental
- Price
- EHAB $9.69
- TERN $3.00
- Analyst Decision
- EHAB Hold
- TERN Buy
- Analyst Count
- EHAB 3
- TERN 5
- Target Price
- EHAB $8.50
- TERN $18.38
- AVG Volume (30 Days)
- EHAB 294.0K
- TERN 1.0M
- Earning Date
- EHAB 05-07-2025
- TERN 05-16-2025
- Dividend Yield
- EHAB N/A
- TERN N/A
- EPS Growth
- EHAB N/A
- TERN N/A
- EPS
- EHAB N/A
- TERN N/A
- Revenue
- EHAB $1,032,300,000.00
- TERN N/A
- Revenue This Year
- EHAB $5.33
- TERN N/A
- Revenue Next Year
- EHAB $4.86
- TERN N/A
- P/E Ratio
- EHAB N/A
- TERN N/A
- Revenue Growth
- EHAB N/A
- TERN N/A
- 52 Week Low
- EHAB $6.85
- TERN $1.87
- 52 Week High
- EHAB $10.70
- TERN $11.40
- Technical
- Relative Strength Index (RSI)
- EHAB 75.75
- TERN 50.81
- Support Level
- EHAB $7.89
- TERN $2.96
- Resistance Level
- EHAB $8.12
- TERN $3.62
- Average True Range (ATR)
- EHAB 0.29
- TERN 0.26
- MACD
- EHAB 0.18
- TERN 0.04
- Stochastic Oscillator
- EHAB 97.66
- TERN 50.40
About EHAB Enhabit Inc.
Enhabit Inc provides home health and hospice services in the United States. Its reportable segments are Home Health and Hospice. The Home Health segment includes a comprehensive range of Medicare-certified home nursing services to adult patients in need of care. These services include, among others, skilled nursing, physical, occupational, and speech therapy, medical social work, and home health aide services. The Hospice segment focuses on the quality of life for patients who are experiencing an advanced, life-limiting illness while treating the person and symptoms of the disease, rather than the disease itself. The company generates a majority of its revenue from the Home Health segment.
About TERN Terns Pharmaceuticals Inc.
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases.